Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study

Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study

Blog Article

Purpose: The aim of this study was to investigate the effect of androgen deprivation therapy (ADT) on the health-related quality of life (HRQOL) of patients with prostate cancer (PC) and compare the changes in the HRQOL between ADT alone and ADT plus intensity-modulated radiation therapy (IMRT).Materials and methods: Patients with PC were prospectively recruited between October 2018 and April 2020.The European AUTUMN ANGEL Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the PC-specific module (PR25) were administered before ADT (baseline) and at 3, 6, and 12 months after ADT.All patients received subcutaneous injections of 45 mg leuprolide acetate at 6-month intervals for 12 months.Results: Fifty-five of the 71 patients (77.

5%) completed the 12-month study.Twenty-two of the 55 patients received IMRT.There were no differences in the baseline characteristics with respect to IMRT.Compared with baseline, physical function and role function deteriorated after 3 months (p = 0.003, p = 0.

019).However, the global quality Medical and Ambulatory supplies / Clinical Laboratory of life (QOL) did not change over time.The symptom scales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire indicated that there was a statistically significant deterioration in dyspnea and fatigue symptoms at 12 months (p = 0.004, p = 0.004).

Responses to the QLQ-PR25 revealed that patients experienced an increase in hormonal treatment-related symptoms after 3, 6, and 12 months (p = 0.002, 0.001, and 0.004).Comparisons between the ADT group and ADT plus IMRT group showed that body function and role function did not differ between the two groups (p = 0.

815, p = 0.759), and there was also no difference in global QOL (p = 0.624).Conclusion: Our results indicate that treatment with leuprolide acetate at 6-month intervals was not accompanied by changes in global QOL, despite deterioration of body and role functions and hormonal treatment-related symptoms.The combination of ADT and IMRT did not lead to additional deterioration in the HRQOL.